Cell No. : Cell Name
RCB1275 : TUHR10TKB
update : 2024/01/25
|
| Comment | Japanese renal carcinoma cells expressing HLA-A2402. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Kawai, Kouji & Ohno, Tadao
|
| Originator |
Liu Shu Qin
|
| Year of deposit |
1996
|
| Another name |
OgTs
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
69 years
|
| Tissue |
kidney
|
| Classification |
cancer
|
| Year of origin |
1996
|
|
Lifespan |
infinite
|
| Morphology |
epithelial-like
|
| Cellosaurus(Expasy) |
CVCL_5952
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
RPMI1640 + 10% FBS
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin
|
Culture information
|
Passage ratio |
|
1 : 4 split
|
| SC frequency |
|
Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
41-84(50) : 41(12),42(13),44(1),81(4),82(9),83(3)/
|
| STR(human) |
|
OK
|
| Images |
deposit info | lot info |
|
|
|
| Reference information |
Reference |
1
|
| User's Publication |
12
|
| User's Publication |
|
18231
Grubb T, Maganti S, Krill-Burger JM, Fraser C, Stransky L, Radivoyevitch T, Sarosiek KA, Vazquez F, Kaelin WG, Chakraborty AA.
A Mesenchymal Tumor Cell State Confers Increased Dependency on the BCL-XL Antiapoptotic Protein in Kidney Cancer
Clin Cancer Res
2022
28(21):4689-4701
PubMed ID: 35776130
DOI: 10.1158/1078-0432.CCR-22-0669
|
|
20629
Stransky LA, Vigeant SM, Huang B, West D, Denize T, Walton E, Signoretti S, Kaelin WG Jr.
Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway.
Proc Natl Acad Sci U S A
2022
119(14):e2120403119
PubMed ID: 35357972
DOI: 10.1073/pnas.2120403119
|
|
16366
Emberley E, Pan A, Chen J, Dang R, Gross M, Huang T, Li W, MacKinnon A, Singh D, Sotirovska N, Steggerda SM, Wang T, Parlati F.
The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma
PLoS One
2021
16(11):e0259241
PubMed ID: 34731180
DOI: 10.1371/journal.pone.0259241
|
|
10005
Soki Kashima, Takuya Maeda, Kyoko Masuda, Seiji Nagano, Takamitsu Inoue, Masashi Takeda, Yuka Kono, Takashi Kobayashi, Shigeyoshi Saito, Takahiro Higuchi, Hiroshi Ichise, Yuka Kobayashi, Keiko Iwaisako, Koji Terada, Yasutoshi Agata, Kazuyuki Numakura, Mitsuru Saito, Shintaro Narita, Masaki Yasukawa, Osamu Ogawa, Tomonori Habuchi, Hiroshi Kawamoto
Cytotoxic T Lymphocytes Regenerated From iPS Cells Have Therapeutic Efficacy in a Patient-Derived Xenograft Solid Tumor Model
iScience
2020
23(4):100998
PubMed ID: 32259478
DOI: 10.1016/j.isci.2020.100998
|
|
10839
Tsuchida A, Senda M, Ito A, Saito S, Kiso M, Ando T, Harduin-Lepers A, Matsuda A, Furukawa K, Furukawa K.
Roles of GalNAc-disialyl Lactotetraosyl Antigens in Renal Cancer Cells.
Sci Rep
2018
8:7017
PubMed ID: 29728594
DOI: 10.1038/s41598-018-25521-6
|
|
3741
Saleeb RM, Farag M, Lichner Z, Brimo F3, Bartlett J, Bjarnason G, Finelli A, Rontondo F, Downes MR, Yousef GM
Modulating ATP binding cassette transporters in papillary renal cell carcinoma type 2 enhances its response to targeted molecular therapy.
Mol Oncol
2018
12(10):1673-1688
PubMed ID: 29896907
DOI: 10.1002/1878-0261.12346
|
|
12964
Kato T, Inoue H, Imoto S, Tamada Y, Miyamoto T, Matsuo Y, Nakamura Y, Park JH.
Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells
Oncotarget
2016
7(14):17652-64
PubMed ID: 26933922
DOI: 10.18632/oncotarget.7755
|
|
6387
Minami K, Chano T, Kawakami T, Ushida H, Kushima R, Okabe H, Okada Y, Okamoto K.
DNMT3L is a novel marker and is essential for the growth of human embryonal carcinoma.
Clin Cancer Res
2010
16(10):2751-9
PubMed ID: 20460473
DOI: 10.1158/1078-0432.CCR-09-3338
|
|
3396
Yamada, Daisuke, Kikuchi, Shinji, Williams, Yuko N, Sakurai-Yageta, Mika, Masuda, Mari, Maruyama, Tomoko, Tomita, Kyoichi, Gutmann, David H, Kakizoe, Tadao, Kitamura, Tadaichi, Kanai, Yae, Murakami, Yoshinori
Promoter hypermethylation of the potential tumor suppressor DAL-1/4.1B gene in renal clear cell carcinoma.
Int J Cancer
2006
118:916-23
PubMed ID: 16152585
DOI: 10.1002/ijc.21450
|
|
5012
Kawakami T, Chano T, Minami K, Okabe H, Okada Y, Okamoto K.
Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.
Hum Mol Genet
2006
15(6):821-30
PubMed ID: 16439445
DOI: 10.1093/hmg/ddl001
|
|
14006
Hirota E, Yan L, Tsunoda T, Ashida S, Fujime M, Shuin T, Miki T, Nakamura Y, Katagiri T.
Genome-wide gene expression profiles of clear cell renal cell carcinoma: identification of molecular targets for treatment of renal cell carcinoma
Int J Oncol
2006
29(4):799-827.
PubMed ID: 16964377
|
|
6450
Tokinaga K, Okuda H, Nomura A, Ashida S, Furihata M, Shuin T.
Hypermethylation of the RASSF1A tumor suppressor gene in Japanese clear cell renal cell carcinoma.
Oncol Rep
2004
12(4):805-10
PubMed ID: 15375503
|
Back
Top
CELL BANK Website
